A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).
about
The central GLP-1: implications for food and drug rewardExendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosisExenatide and the treatment of patients with Parkinson's diseaseExenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.Safety and adverse effects associated with GLP-1 analogues.Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).Effect of renal impairment on the pharmacokinetics of exenatideInvestigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.Exenatide: a new option for the treatment of type 2 diabetes.Evolution of exenatide as a diabetes therapeutic.GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.Role of lateral septum glucagon-like peptide 1 receptors in food intakeExendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in miceComparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.Incretin-based therapies: viewpoints on the way to consensus.Population pharmacokinetics of exenatideGLP-1 based therapies: differential effects on fasting and postprandial glucose.Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.Incretins: their physiology and application in the treatment of diabetes mellitus.Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.Do we know the true mechanism of action of the DPP-4 inhibitors?Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men
P2860
Q21129358-B5961082-0B70-414C-B16F-1E0AC7FFC7A2Q28481242-0F651EDA-E07E-43CB-B096-84A342F01716Q30540208-82097D4B-3E09-4445-A34C-C9C2FABF45CCQ34530205-08FE8B4D-2096-46F1-830F-9DA61A319E0EQ34581781-AB5F593E-D5D9-406E-8188-5B97339AE80FQ34614211-CD25CFD2-8FC0-4CE5-9AA4-90178E4580A7Q35037304-BDBEB7EE-8F45-4220-8E61-C44FC2CA08C6Q36024667-966AE40A-A8FB-416F-9BE0-55F25243BCFDQ36543063-218697FA-B1C0-44E4-B376-910047ED8F2FQ36593147-9447D5B8-B260-4073-A17B-2767386F3AD3Q36598110-918B699A-2AD9-4EEB-B1FC-BBC72C471EF3Q36877205-EF10CD21-D23A-46BB-9E8C-3F022B3565B2Q37078997-8B8CC6B2-4185-475E-8AD4-DD9C52DA0722Q37139700-2EB63E09-4B11-4097-941C-C3933CCE149AQ37179909-9BD5C6B8-267D-4F5A-BB3F-1713328CDCCBQ37510200-F90914C5-FE4B-4EDE-8A23-382E4797E775Q37624267-57C3310C-D678-40FF-AC07-8B2129865E7DQ37639905-7E232F18-1C35-43C2-ACE7-CC06B5BD300EQ37974712-550E3A3C-2C68-46DB-8263-31EA51767D82Q38179267-B7709814-32C1-470E-8F62-42FC0FC2736EQ38225693-55C176DA-107A-4D61-96A0-0C571BD3E40CQ39220482-68DF1524-20EF-4A98-BCA7-6DFFC07EB076Q39329866-621EEF98-6540-4FA3-8936-F301CBE9A84FQ43172648-BBF5E229-8D1E-4646-B27C-60AD8E1E5649Q44835737-99D76985-B3D2-459F-B6BB-28379AE6741EQ49971015-FDB0366D-3D52-4187-8779-8ED139BF93ACQ51249870-625DF9AD-409C-4EE9-BC97-62B51A043FBEQ51424631-12C7E701-ADF3-42D4-AB71-60E7B26C6E9EQ58167460-57F482D2-9C77-4660-8734-DF8CA1D81AA2
P2860
A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A randomized, open-label, cros ...... enatide (synthetic exendin-4).
@en
A randomized, open-label, cros ...... enatide (synthetic exendin-4).
@nl
type
label
A randomized, open-label, cros ...... enatide (synthetic exendin-4).
@en
A randomized, open-label, cros ...... enatide (synthetic exendin-4).
@nl
prefLabel
A randomized, open-label, cros ...... enatide (synthetic exendin-4).
@en
A randomized, open-label, cros ...... enatide (synthetic exendin-4).
@nl
P2093
P1476
A randomized, open-label, cros ...... enatide (synthetic exendin-4).
@en
P2093
Eh Moo Carr
Evelyn Zabala
Federico Calara
Kristin Taylor
Mark Fineman
Matthew Wintle
P304
P356
10.1016/J.CLINTHERA.2005.02.008
P577
2005-02-01T00:00:00Z